The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-23. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In February 2017, Indian ambassador to the U.S. Navtej Sarna hosted a reception for the National Governors Association (NGA), which was attended by the Governors of 25 states and senior representatives of 3 more states. This was the first time such an event has occurred. Explaining the reason for the gathering, Virginia Governor and NGA Chair Terry McAuliffe stated that "India is America's greatest strategic partner". He further added, "We clearly understand the strategic importance of India, of India–U.S. relations. As we grow our 21st century economy, India has been so instrumental in helping us build our technology, medical professions. We recognise a country that has been such a close strategic ally of the US. That's why we the Governors are here tonight." McAuliffe, who has visited India 15 times, also urged other Governors to visit the country with trade delegations to take advantage of opportunities. In October 2018, India inked the historic agreement worth US$5.43 billion with Russia to procure four S-400 Triumf surface-to-air missile defence system, one of the most powerful missile defence systems in the world ignoring America's CAATSA act. The U.S. threatened India with sanctions over India's decision to buy the S-400 missile defense system from Russia. The United States also threatened India with sanctions over India's decision to buy oil from Iran. According to the President of the U.S.-India Strategic Partnership Forum (USISPF), Mukesh Aghi: "sanctions would have a disastrous effect on U.S.-India relations for decades to come.
Trisenox – Almac Pharma – 1 mg/mL concentrate for intravenous therapy. Trisenox is packaged in 10 mL ampoules for single use. The ampoules contain a pure solution of arsenic trioxide, without preservatives, and also contain sodium hydroxide and hydrochloric acid. The solution has a pH of 7–9. The drug should be stored at room temperature and must not be frozen. After withdrawing the solution from the ampoule, it should be diluted in 100–250 mL of 5% glucose or saline solution. Arsenic trioxide should not be mixed or administered in the same infusion with other medications. In pharmaceutical compounding, arsenic trioxide was used in a 1:10 trituration with lactose (Trituratio Acidi arsenicosi 1/10). To prepare the trituration, one part arsenic trioxide is placed in a mortar, and while continuously grinding, nine parts of lactose are added in portions. Achieving a uniformLy distributed trituration requireson
==== Belgium ==== Until 2024, several formulations of pseudoephedrine were available over-the-counter in Belgium. However, new legislation came into effect in November 2024, banning the over-the-counter sale of all medicines containing pseudoephedrine.
Sources: en.wikipedia.org
=== NutraSweet Company === In 1985, Monsanto bought G.D. Searle, and the aspartame business became a separate Monsanto subsidiary, NutraSweet. In March 2000, Monsanto sold it to J.W. Childs Associates Equity Partners II L.P. European use patents on aspartame expired beginning in 1987, with the US patent following suit in 1992.
The first sizeable batch of Boer prisoners taken by the British consisted of those captured at the Battle of Elandslaagte on 21 October 1899. Initially, these POWs were held on troopships in Simons Bay until POW camps in Cape Town and Simonstown were completed. In total, six prisoner of war camps would be set up in South Africa. As numbers grew, the British decided they did not want them kept locally. The capture of 4000 POWs in February 1900 was a key event, which made the British realise they could not accommodate all POWs in South Africa. The British feared they could be freed by sympathetic locals. Moreover, they already had trouble supplying their troops and did not want the added burden of sending supplies for the POWs. Britain therefore sent many POWs overseas. Around 31 prisoner of war camps were consequently set up in British colonies overseas during the war. The first overseas (off African mainland) camps were opened in Saint Helena, which ultimately received about 5,000 POWs. About 5,000 POWs were sent to Ceylon. Other POWs were sent to Bermuda and India.
== Disorder and disease == Intrinsically unstructured proteins have been implicated in a number of diseases. Aggregation of misfolded proteins is the cause of many synucleinopathies and toxicity as those proteins start binding to each other randomly and can lead to cancer or cardiovascular diseases. Thereby, misfolding can happen spontaneously because millions of copies of proteins are made during the lifetime of an organism. The aggregation of the intrinsically unstructured protein α-synuclein is thought to be responsible. The structural flexibility of this protein together with its susceptibility to modification in the cell leads to misfolding and aggregation. Genetics, oxidative and nitrative stress as well as mitochondrial impairment impact the structural flexibility of the unstructured α-synuclein protein and associated disease mechanisms. Many key tumour suppressors have large intrinsically unstructured regions, for example p53 and BRCA1. These regions of the proteins are responsible for mediating many of their interactions. Taking the cell's native defense mechanisms as a model drugs can be developed, trying to block the place of noxious substrates and inhibiting them, and thus counteracting the disease.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.